Cited by 338Autophagy in Disease and TherapyUbiquitin and proteasome pathwaysEndoplasmic Reticulum Stress and Disease

Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells.

Open access
Zhu, K, Dunner, K, McConkey, D J·2010·Oncogene

Abstract

The ubiquitin-proteasome and lysosome-autophagy pathways are the two major intracellular protein degradation systems that work cooperatively to maintain homeostasis. Proteasome inhibitors (PIs) have clinical activity in hematological tumors, and inhibitors of autophagy are also being evaluated as potential antitumor therapies. In this study, we found that chemical PIs and small interfering RNA-mediated knockdown of the proteasome's enzymatic subunits promoted autophagosome formation, stimulated autophagic flux, and upregulated expression of the autophagy-specific genes (ATGs) (ATG5 and ATG7) in some human prostate cancer cells and immortalized mouse embryonic fibroblasts (MEFs). Upregulation of ATG5 and ATG7 only occurred in cells displaying PI-induced phosphorylation of the eukaryotic translation initiation factor 2 alpha (eIF2alpha), an important component of the unfolded protein responses. Furthermore, PIs did not induce autophagy or upregulate ATG5 in MEFs expressing a phosphorylation-deficient mutant form of eIF2alpha. Combined inhibition of autophagy and the proteasome induced an accumulation of intracellular protein aggregates reminiscent of neuronal inclusion bodies and caused more cancer cell death than blocking either degradation pathway alone. Overall, our data show that proteasome inhibition activates autophagy through a phospho-eIF2alpha-dependent mechanism to eliminate protein aggregates and alleviate proteotoxic stress.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/onc.2009.343

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Previous studies have shown that inhibition of the proteasome system induces autophagy in vivo and in vitro.

    “Previous studies have shown that inhibition of the proteasome system induces autophagy in vivo and in vitro (Iwata et al., 2005; Pandey et al., 2007; Zhu et al., 2010).”

    From Inducible Rpt3, a Proteasome Component, Knockout in Adult Skeletal Muscle Results in Muscle Atrophy (2020) · cites this paper as Zhu et al., 2010

    The Abstract (page not provided) reports that proteasome inhibition promoted autophagy in cultured human prostate cancer cells and mouse embryonic fibroblasts, supporting the in vitro portion. The study does not report an in vivo test, so Zhu et al. does not support that portion of the citing sentence. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • In a previous study, inhibition of the proteasome by specific silencing of a proteasome subunit stimulated increases in Atg5 and Atg7 levels.

    “In a previous study, inhibition of the proteasome by specific silencing of a proteasome subunit also stimulated increases in Atg5 and Atg7 levels (Zhu et al., 2010).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Zhu, K., Dunner, K., & McConkey, D. J.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
Corresponding author
McConkey, D J
Venue
Oncogene
Published
2009-11-02
Volume
29
Issue
3
Pages
451-462
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W2158892689
Cited by
338
References
46
Citations by year
2026: 10 · 2025: 8 · 2024: 14 · 2023: 18 · 2022: 18 · 2021: 15 · 2020: 18 · 2019: 21 · 2018: 21 · 2017: 16 · 2016: 26 · 2015: 27 · 2014: 28 · 2013: 31 · 2012: 29
FWCI
15.06
Type
journal article
Language
en
Open access
Locations
  • Oncogene (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • U.S. Department of Defense
  • AstraZeneca
  • National Institutes of Health
  • University of Texas MD Anderson Cancer Center
  • School of Medicine, Indiana University
  • National Cancer Institute (CA-16672, R01CA127494, P30CA016672)
  • DOD Prostate Cancer Research Program
Topics
  • Health Sciences › Medicine › Epidemiology › Autophagy in Disease and Therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
Keywords
proteasome inhibitors, autophagy, prostate cancer, eIF2α phosphorylation, ATG5, ATG7, protein aggregation, proteotoxic stress, unfolded protein response, ubiquitin-proteasome system, cytoprotection, autophagic flux
MeSH terms
Bortezomib, Autophagy-Related Protein 5, Autophagy-Related Protein 7, Animals, Autophagy, Boronic Acids, Cell Line, Cell Survival, Humans, Lactones, Lysosomes, Male, Microtubule-Associated Proteins, Phagosomes, Prostatic Neoplasms, Protease Inhibitors, Pyrazines, Pyrroles, Immunoblotting, Reverse Transcriptase Polymerase Chain Reaction, RNA Interference, Ubiquitin-Activating Enzymes, Cell Line, Tumor, Microscopy, Electron, Transmission, Proteasome Endopeptidase Complex, Proteasome Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review